| Retail: $5 Approved for .25 Category A+ Credits
Treatment for non-small cell lung cancer (NSCLC) typically consists of a combination of surgery, radiation therapy, chemotherapy, targeted therapy, or immunotherapy. The success rate of these combinations is poor; fewer than approximately 23% of patients survive 5 years. During the past 2 decades, stereotactic body radiation therapy and immunotherapy have generated high hopes for improving outcomes in patients with a variety of cancers, including NSCLC. Recently, the strategy of employing these treatments has emerged as a potential treatment in a small subset of patients.
This quiz is the companion to the column “Immunotherapy Combined with Stereotactic Body Radiation Therapy for Non-small Cell Lung Cancer,” which appears in the Spring 2021 Radiation Therapist journal.
This activity may be available in multiple formats or from different sponsors. ARRT regulations state that an individual may not repeat a self-learning activity for credit if it was reported in the same biennium.
Free access is included with membership. All titles for which you have not previously earned CE credit appear in your CE library.
Not a member? Call Member Services to join 800-444-2778
Product Information
Online version of Radiation Therapist